AR and prostate carcinoma: Another study targeting AR signaling comprised the combination treatment of androgen-accustomed DuCaP-N prostate cancer cells with the HDAC inhibitor TSA, the anti-androgen bicalutamide, and the 5α-reductase inhibitor finasteride.